Cancer care has evolved over the past 30 years. The development of more aggressive cancer screening programs, improvement of diagnostic testing, and incorporation of novel targeted therapies resulted in a higher rate of cancer diagnosis with a concomitant increase of cancer survival.

While conventional chemotherapy has been known for decades to induce detrimental effects on the heart and peripheral vasculature, the novel agents might also have harmful off-target consequences. Cardiovascular toxicity of anticancer therapy and existing cardiovascular diseases are the leading causes of late morbidity and mortality in  cancer survivors competing with recurrent malignancies.

Therefore, a need for closer collaboration between cardiologists, oncologists, and hemato-oncologists arises. This clinical need has brought accelerated clinical and basic research of tumor cellular signaling and genetics, leading to expanding research interplay between these disciplines.

We herein launch the third International Meeting in Cardio-oncology to be held virtually on January 13-14, 2021.

​

The main aims of this meeting are:

​

• To facilitate the establishment of services and develop the field of cardio-oncology in Israel.

• To mitigate the COVID-19 pandemic effects on cardio-oncology.

• To bring together cardiologists, oncologists, hemato-oncologists, and general practitioners from Israel and worldwide.

• To bring together national and international medical and para-medical disciplines involved, including the fields of imaging, biomarkers, others.

• To provide a stage to basic scientists and pharmacologic companies developing novel antineoplastic treatment regimens.

• To contribute to the development of ongoing international recommendations and guidelines in the field.

​

Multidisciplinary faculty directed by prominent Israeli experts in the field of cardiology, oncology, and hemato-oncology with the close support of relevant professional societies and the International Cardio-Oncology Society (ICOS) developed the meeting agenda.